Interestingly, such a use of growth factors, serving as prognostic factors on the basis of the negative correlation of the levels of FGF-2 and VEGF, has also been confirmed in a study involving pre-clinical blood samples from patients many years before clinical MM diagnosis [108]. The gene discussed is FGF2; the disease is Miyoshi myopathy.